A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)

Summary

This is a multicenter, open-label, Phase 1 study of AUR104 in adult patients with select Relapsed/Refractory (R/R) Lymphoid Malignancies. The main objective of the study is to evaluate the safety and tolerability of the study drug AUR104.In this study, safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AUR104 will be evaluated in dose escalation manner.

Timeline

Start

2024-12-12

Primary completion

2026-02-10

Completion

2026-02-10

Outcome

Outcome not reported

Stopped (Enrollment): “Patient recruitment problems”

Drugs

Indications